We describe the exceptional case of spinal cord malformation, associating neurenteric cyst, and cervical vertebral malformation, initially presenting as torticollis. A 4-month-old child presented with torticollis to the right since birth. A cervical spine X-ray revealed suspicious findings of fusion anomaly, and a cervical spine CT showed extensive segmentation-fusion anomaly with an anterior and posterior bony defect in the C1–6 vertebrae. A cervical spine MRI revealed extensive segmentation-fusion anomaly with an anterior bony defect, and the spinal cord split forward and backward at the C3 level, showing two hemicords. The anterior half of the hemicord and dural sac extended to the right inferior side, towards the upper blind end of esophageal duplication, and the posterior half joined the hemicord at the back and C6 level. After multidisciplinary collaboration, follow-up and conservative treatment were planned. At 12 months, he had developmental delay, and torticollis showed little improvement. No neurological abnormalities have been observed. The patient plans to undergo surgery for the cervical spine fusion anomaly. Cervical spine X-rays should always be performed when assessing a patient with torticollis to rule out cervical vertebral segmentation anomalies, despite the rarity of the condition.
Aims: To develop and evaluate a novel AI-based video analysis tool for the quantitative assessment of “Places Pegs in” and “Blue Board” tasks in the Bayley Scales of Infant Development (BSID-II). Methods: A prospective cohort study was conducted from February 2022 to December 2022, including children aged 12–42 months referred for suspected developmental delay. Participants were evaluated using the BSID-II, and their performances on the two tasks were video recorded and analyzed with the novel tool. Sensitivity and specificity were determined by comparing the tool’s results to standard BSID-II assessments by therapists. Data collected included total time, number of trials, successful trials, and time and spatial intervals for each trial. Children were classified into typically developing (TD) (MDI ≥ 85) and developmental delay (DD) (MDI < 85) groups based on their mental developmental index (MDI). Results: A total of 75 children participated in the study, and the mean values of MDI and PDI for the enrolled children were 88.9 ± 18.7 and 80.0 ± 16.7. The “Places Pegs in” had 86.5% sensitivity and 100% specificity; the “Blue Board” had 96.9% sensitivity and 89.5% specificity. Differences in cumulative successes over time were observed between age groups and TD and DD groups. The tool automatically calculated maximum successes at specific time points. Interpretation: The AI-based tool showed high predictive accuracy for BSID-II tasks in children aged 12–42 months, indicating potential utility for developmental assessments.
Botulinum toxin type A (BTX-A) injection is a commonly used therapeutic intervention for upper limb spasticity in stroke patients. This study was designed as a randomized, active-drug-controlled, double-blind, multicenter, phase 3 clinical trial to evaluate the safety and efficacy of Liztox® in comparison to onabotulinum toxin A (Botox®) for individuals with post-stroke upper limb spasticity. The primary outcome was the alteration in wrist flexor muscle tone from the initial assessment to the fourth week, evaluated using the modified Ashworth scale (MAS). Secondary outcomes included MAS score changes for the wrist at weeks 8 and 12 from baseline; MAS score changes for finger and elbow flexors; and changes in the Disability Assessment Scale (DAS), Subject’s Global Assessment (SGA), the Investigator’s Global Assessment (IGA), and Caregiver Burden Scale (CBS) at weeks 4, 8, and 12 from baseline. The MAS score for wrist flexor spasticity decreased by −1.14 ± 0.59 in the Liztox® group and −1.22 ± 0.59 in the Botox® group from baseline to week 4. The difference [97.5% confidence interval (CI)] between the test and control groups was 0.08 [−∞, 0.26], confirming the non-inferiority of the test group compared to the control group. Furthermore, there were consistent improvements in the IGA, SGA, and CBS scores across all assessment intervals, with no statistically significant variances detected between the two groups. No safety-related concerns were reported during the study. In conclusion, Liztox® injection proved to be a secure and efficacious intervention for managing upper extremity spasticity in post-stroke patients.